Investing in Transformative Biotech Companies
The Aescap funds invest in publicly traded biotech / life sciences companies. They invest in high-growth, innovative companies that develop and market new medicines and in some cases diagnostics and medical devices. The funds comply with the Dutch Authority Financial Markets (AFM) and are managed by a broad and experienced team with a great track record. A team that has invested a significant amount of money in the Aescap funds themselves. Aescap aims to generate preferred financial returns by choosing a focused investment approach picking around 20 companies per fund. It acts as a private equity player on the stock market by being heavily involved in the companies it invests in. The name Aescap is derived from ‘Aesculapius’, the Roman god of Medicine, and ‘Capital’.
Net Performance
Per November 30, 2022
Net IRR
+6.5%
Net 2022 YtD
-18.3%
Net IRR
N/A
Net 2022 YtD
-6.6%
Impact
The companies in the portfolios of the Aescap biotech funds address medical needs that are not met by products available today.
We believe everybody has the right to receive the best medical care available. Aescap’s investments have a substantial positive impact on society and have already resulted in an improvement of the quality of live of millions of people worldwide.
Update via Webcast
Our presentation for existing and interested investors is currently replaced by a webcast. The next webcast will be held on December 13, 2022 at 15:00 CET.
Meet the Investment Team
The Aescap investment team, led by portfolio manager Patrick Krol, consists of experienced professionals with different backgrounds in the health care industry. Aescap aims to providing a good financial return to their investors, and in parallel contribute to improving the well-being of millions of people. The team invests in the Aescap funds themselves with over 25 million euro.
Biotech Market
The biotech sector, also known as the life sciences sector, is a large and fast-growing sector, driven by an aging population and a high pace of innovation. New medicines like RNA, gene and cell therapies will replace the vast majority of medicine over the coming decades. With around 1000 public biotech companies in the EU and US, it requires sector specific expertise to find de-risked companies with a high earning power that are still undervalued.
Subscribe to our Newsletter here.
Investment Strategy
Find out more about Aescap in this animation.
- Next-generation medicine
- Outstanding management
- High-growth companies
- Diversification within our focus
- Undervalued companies
- Buy and Sell discipline
Latest news
Aescap Genetics Newsletter Q3 2022
From treatment of symptoms to cure. The number of genetic medicines that are so advanced in R&D that they are tested on humans has been increasing by an average of 27% per year since 2016.
Aescap Life Sciences Newsletter Q3 2022
Upward potential of portfolio further increased. The fund made a small positive net performance for the third quarter of 1,8%. Continuous poor market sentiment continued to depress share prices of our portfolio companies despite the present and expected future revenue and profit growth these innovative companies face.
Aescap Life Sciences Newsletter Q2 2022
Solid performance across portfolio. Due to a strong net performance of +13,2% since we published our NAV of mid June, the net performance of the fund for June ended at +8,8%.